1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Baxter International's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was 22.74%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Baxter International's 1-Year ROIIC % or its related term are showing as below:
MEX:BAX's 1-Year ROIIC % is ranked better than 69.17% of 824
companies
in the Medical Devices & Instruments industry
Industry Median: 0.38
vs MEX:BAX: 22.74
Baxter International (MEX:BAX) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Baxter International 1-Year ROIIC % Related Terms
Baxter International 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Baxter International's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BAX vs ALGN, SOLV, COO: 1-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Baxter International's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International 1-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Baxter International's 1-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Baxter International (MEX:BAX) has a 1-Year ROIIC % of 22.74 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Baxter International and its competitors. According to the industry distribution chart, Baxter International ranks #254 out of 824 companies in the Medical Devices & Instruments industry, placing it in the top 30.8%.
Is Baxter International's 1-Year ROIIC % too high?
Baxter International's current 1-Year ROIIC % is 22.74. The Medical Devices & Instruments industry median 1-Year ROIIC % is 0.38. Baxter International's value of 22.74 is 5884.2% above this industry median. Based on the distribution chart, Baxter International ranks #254 out of 824 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Baxter International has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's 1-Year ROIIC % compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #254 out of 824 companies for 1-Year ROIIC %. This puts Baxter International in the upper half of its industry. The industry median 1-Year ROIIC % is 0.38. Baxter International's value of 22.74 is 5884.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Devices & Instruments company?
The median 1-Year ROIIC % among Medical Devices & Instruments companies is 0.38, based on 824 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baxter International's current 1-Year ROIIC % of 22.74 is 5884.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Baxter International and its competitors. For the Medical Devices & Instruments industry, the median 1-Year ROIIC % is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current 1-Year ROIIC % is 22.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (MEX:BAX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN559.81, compared to a current price of MXN368.00 — trading 34.3% below its estimated fair value. The current 1-Year ROIIC % is 22.74 and 5884.2% above the Medical Devices & Instruments industry median of 0.38. Baxter International's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Baxter International (MEX:BAX), the current 1-Year ROIIC % is 22.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (MEX:BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of MXN368.00 is trading 34.3% below its estimated GF Value™ of MXN559.81.
GuruFocus considers Baxter International to be Possible Value Trap.
Key valuation signals for MEX:BAX:
1-Year ROIIC %: 22.74
GF Value™: MXN559.81 vs. price of MXN368.00 (34.3% below fair value)
Industry Position: 5884.2% above the Medical Devices & Instruments median (#254 of 824)
No single metric tells the full story. See the MEX:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
44GF Score
Get the complete analysis for MEX:BAX
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BAX has been successfully added to your 
